Drugdocs | Venclexta

An independent source of information on U.S. brand name drugs for health professionals

An independent source of information on U.S. brand name drugs for health professionals

Venclexta

Chemical Name	venetoclax
Dosage Form	Tablet (oral; 10 mg, 50 mg, 100 mg)
Drug Class	Inhibitors
System	Blood
Company	AbbVie Inc.
Approval Year	2016

Indication

For chronic lymphocytic leukemia in patients with a specific chromosomal abnormality.
In combination with azacitidine or decitabine or low-dose cytarabine for the treatment of newly-diagnosed acute myeloid leukemia in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Last updated on 12/21/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document Title	Year	Source
Venclexta (venetoclax) Prescribing Information	2019	AbbVie Inc., North Chicago, IL

Document Title	Year	Source
Venetoclax for treating chronic lymphocytic leukaemia	2017	NICE

Document Title	Year	Source
Novel Targeted Therapies for Chronic Lymphocytic Leukemia in Elderly Patients: A Systematic Review	2020	Clinical Lymphoma, Myeloma and Leukemia
The efficacy and adverse events of venetoclax in combination with hypomethylating agents treatment for patients with acute myeloid leukemia and myelodysplastic syndrome: a systematic review and meta-analysis.	2020	Hematology
Efficacy and Safety of Bcl-2 Inhibitor Venetoclax in Hematological Malignancy: A Systematic Review and Meta-Analysis of Clinical Trials	2019	Frontiers in Pharmacology

Document Title	Year	Source
Clinical practice guidelines for diagnosis and treatment of chronic lymphocytic leukemia (CLL) in the Netherlands.	2018	Clinical Lymphoma, Myeloma & Leukemia